Product Description
anti-CD19-chimeric antigen receptor (CAR) lentiviral vector-transduced autologous T cells (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT02706405)
Mechanisms of Action: CAR-T,CD19
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fred Hutchinson Cancer Research Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCI-2015-02286 | P1 |
Terminated |
Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin |
2021-05-28 |